Archive · 31 Jul 2025
Orchid Pharma Reclaims Antibiotic Rights, Stock Surges
Imagine a company called Orchid Pharma that made a special medicine called Enmetazobactam.
They had let other companies sell it in different places.
Now, Orchid has bought back the rights to sell this medicine everywhere in the world!
This is a big deal because the medicine can fight off nasty germs.
The medicine is already approved for use in Europe and the US.
Experts think it could make a lot of money.
Orchid is happy to have its medicine back, and everyone is watching to see how well it does.
Orchid Pharma's shares rose by 5% after acquiring global rights to its antibiotic.
Orchid Pharma regained full ownership of the antibiotic Enmetazobactam.
The drug was previously licensed to Allecra Therapeutics and others.
Enmetazobactam has received regulatory approval in the EU and US.
Market analysts are watching European sales and US out-licensing potential.
- Who
- Orchid Pharma bought back the rights from Allecra Therapeutics.
- What
- Orchid Pharma acquired full global rights to its antibiotic, Enmetazobactam.
- When
- Shares surged on Thursday, July 31.
- Where
- The antibiotic is marketed globally, including in Europe and India.
- Why
- To regain control of its novel antibiotic and potentially increase profits.
- Company
- Orchid Pharma Ltd.
- Stock Movement
- Up 5%
- Antibiotic Name
- Enmetazobactam
- Previous Licensee
- Allecra Therapeutics
- Regulatory Approval
- EU, US
- Global Peak Sales Potential
- $150-200 million